Crinetics Pharmaceuticals Inc
CRNX
Market Cap$2.83B
Close$
$0.57
98.1% downside
Current Fair Value
98.1% downsideOvervalued by 98.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.83 Billion |
|---|---|
| Enterprise Value | $2.78 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.69 |
| Beta | 0.28 |
| Outstanding Shares | 93,102,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.55 |
|---|---|
| PEG | -19.18 |
| Price to Sales | - |
| Price to Book Ratio | 2.31 |
| Enterprise Value to Revenue | 3662.96 |
| Enterprise Value to EBIT | -7.38 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers